What happens when one disinfectant cannot satisfy every IFU? At AHE in New Orleans, Diane Cullen discusses weighted risk assessment, documenting difficult decisions, and why infection prevention and EVS need to work together.
|Articles|August 2, 2013
Hospital Participates in Trial of Investigational Vaccine for Prevention of Clostridium difficile
Advertisement
Mark Martens, MD, chief of obstetrics and gynecology at Jersey Shore University Medical Center, announces that the hospital is participating in a clinical study to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. While most types of healthcare-associated infections (HAIs) are declining, C. diff is emerging as a leading cause of life-threatening HAIs worldwide.
In 2010, the Food and Drug Administration (FDA) granted fast-track designation to the investigational C. diff vaccine candidate being developed by Sanofi Pasteur. The fast-track program of the FDA is designed to facilitate the development and expedite the review of new investigational drugs and vaccines that are intended to treat or prevent serious or life-threatening conditions and demonstrate the potential to address unmet medical needs.
Source: Meridian Health
Advertisement
Related to this article
Turnover pressure can leave critical OR cleaning steps unfinished. Karen deKay, MSN, RN, EBP-C, CNOR, CIC, FAPIC, examines common gaps in environmental hygiene and how shared responsibilities, attention to disinfectant contact time, and ongoing education can help teams strengthen practices between cases.
A patient with fever and no recent travel could still have dengue. Florida’s local transmission highlights why clinicians and infection preventionists should look beyond travel history and recognize warning signs.
High contact follow-up rates suggest progress, but who is being missed? Inside the DRC’s Ebola response, shortages, strained treatment centers, and gaps in community trust reveal a more complicated story.
Sterile processing professionals face constant interruptions, cognitive overload, increasingly complex devices, and hundreds of IFUs. Randalyn Harreld, CRCST, FHSPA, explains why health care organizations must address the human factors behind SPD performance rather than expecting frontline professionals to simply absorb ever-increasing complexity.
Long-acting HIV therapies promise greater convenience, but fewer doses alone may not solve adherence or access challenges. Lloyd Bibby and Pooja Goyal, MS(Pharm), discuss patient choice, weekly oral and injectable therapies, health system capacity, equitable access, and the real-world measures that will define success.
This week on Infection Control Today, the stories ranged from emerging drug-resistant pathogens circling the globe to a landmark decade of surface science—all against a backdrop of ongoing outbreaks and a hard look at what the profession owes its own workforce.
At AHE 2026 in New Orleans, The Beryl Institute's Stacy Palmer discussed 8 guiding principles for experience excellence and why EVS professionals influence far more than environmental cleanliness. Their interactions, workplace culture, and connection with patients help shape the overall human experience of health care.
Advertisement
Advertisement
Trending on Infection Control Today
1
When the Ebola Outbreak is Spreading Faster Than the Response Can Follow
2
Pathogen Pulse: The Alarming Rise of Dengue in Florida
3
Sterile Processing Burnout and Cognitive Overload: How Interruptions, IFUs, and Human Factors Affect Patient Safety
4
Long-Acting HIV Treatment and PrEP: How Weekly Oral and Injectable Therapies Could Change Adherence and Patient Choice
5